Corresponding Author: Adam S. Lauring, MD, PhD, Division of Infectious Diseases, Department of Internal Medicine and Department of Microbiology and Immunology, University of Michigan, 1150 W Medical Center Dr, MSRB1 5510B, Ann Arbor, MI 48109-5680 (alauring@med.umich.edu).
Published Online: January 6, 2021. doi:10.1001/jama.2020.27124
Correction: This article was corrected on February 15, 2021, to fix the heading “Spike N453Y and Mink” to the correct substitution of Y453F.
Conflict of Interest Disclosures: Dr Lauring reported receiving personal fees from Sanofi as a consultant on oseltamivir and influenza and personal fees from Roche as a member of a steering committee for a clinical trial of baloxavir and influenza, outside the submitted work. No other disclosures were reported.